Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-22T12:22:15.751Z Has data issue: false hasContentIssue false

8 - Decision Points in Iterative Pharmacotherapy

Published online by Cambridge University Press:  25 March 2024

Joseph F. Goldberg
Affiliation:
Icahn School of Medicine at Mount Sinai, New York
Stephen M. Stahl
Affiliation:
University of California San Diego
Get access

Summary

More often than not, an initial intervention in psychiatry requires modification. Sometimes sooner than later, the clinician must judge whether a medication dose needs adjustment, an augmentation is warranted, or an outright change should occur when something has been tried and deemed to be unsuccessful. Perhaps a new additional diagnosis comes to light (such as alcohol or substance use disorder) requiring its own treatment. Or an insurmountable medication intolerance develops. Or the originally identified target symptoms worsen, metamorphose, or persist long enough after a previous medication change to warrant a further alteration. Other times, changes to a regimen happen not necessarily because sufficient time has elapsed to deem a change necessary, but because a patient’s (or significant other’s) capacity to tolerate negative affect or other elements of distress become saturated, prompting entreaties or outright demands to “do” something that seems more proactive. In all such instances, there is seldom if ever only one correct approach to iterative pharmacotherapy.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Burdick, KE, Braga, RJ, Nnadi, CU, et al.Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: Targeting cognitive dysfunction. J Clin Psychiatry 2012; 73: 103112CrossRefGoogle ScholarPubMed
Coryell, W, Solomon, D, Turvey, C, et al.The long-term course of rapid cycling bipolar disorder. Arch Gen Psychiatry 2003; 60: 914920CrossRefGoogle ScholarPubMed
Faedda, GL, Tondo, L, Baldessarini, RJ, et al.Outcome after rapid versus gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448455CrossRefGoogle Scholar
Goldberg, JF.When further pharmacotherapy is futile. J Clin Psychiatry 2018; 80: 18ac12276CrossRefGoogle ScholarPubMed
Goldberg, JF, Stahl, SM.Practical Psychopharmacology: Translating Findings from Evidence-Based Trials into Real-World Clinical Practice. Cambridge: Cambridge University Press, 2021.CrossRefGoogle Scholar
Khan, A, Fahl Mar, K, Faucett, J, et al.Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry 2017; 16: 181192CrossRefGoogle ScholarPubMed
Kahn, RS, Winter Van Rosum, I, Leucht, S, et al.Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study. Lancet Psychiatry 2018; 5: 797807CrossRefGoogle ScholarPubMed
Leucht, S, Komossa, K, Rummel-Kluge, C, et al.A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152163CrossRefGoogle ScholarPubMed
Meyer, JM, Stahl, SM.The Clinical Use of Antipsychotic Plasma Levels. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
Olfson, M, Marcus, SC, Tedeschi, M, et al.Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163: 101108CrossRefGoogle ScholarPubMed
Papakostas, GI, Thase, ME, Fava, M, et al.Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62: 12171227CrossRefGoogle Scholar
Rohsenow, DJ, Tidey, JW, Miranda, R, et al.Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers. Exp Clin Psychopharmacol 2008; 16: 215222CrossRefGoogle ScholarPubMed
Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006; 163: 19051917CrossRefGoogle ScholarPubMed
Rush, AJ, Wisniewski, SR, Warden, D, et al.Selecting among second-step antidepressant medication monotherapies: Predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008; 65: 870880CrossRefGoogle ScholarPubMed
Sachs, GS, Nierenberg, AA, Calabrese, JR, et al.Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 17111722CrossRefGoogle ScholarPubMed
Schooler, NR, Marder, SR, Chengappa, KNR, et al.Clozapine and risperidone in moderately refractory schizophrenia: A 6-month randomized double-blind comparison. J Clin Psychiatry 2016; 77: 628634CrossRefGoogle ScholarPubMed
Semahegen, A, Torpey, K, Manu, A, et al.Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis. Syst Rev 2020; 9:17CrossRefGoogle Scholar
Turner, EH, Matthews, AM, Linardatos, E, et al.Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252260CrossRefGoogle ScholarPubMed
Turner, EH, Cipriani, A, Furukawa, TA, et al.Selective publication of antidepressant trials and its influence on apparent efficacy: updated comparisons and meta-analyses of newer versus older trials. PLoS Med 2022; 19(1): e1003886CrossRefGoogle ScholarPubMed
van der Loos ML, Mulder, PG, Hartong, EG, et al.Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223231Google Scholar
Wahlbeck, K, Cheine, N, Essali, A, et al.Evidence of clozapine’s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990999CrossRefGoogle ScholarPubMed
Yatham, LN, Mackala, S, Basivireddy, J et al.Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: A randomised, open-label, pilot study. Lancet Psychiatry 2017; 4: 208217CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×